Skip to content

Study · Ex vivo tissue · 2018

8 results

Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.

Giacomini E, Rizzo F, Etna MP, Cruciani M, Mechelli R, Buscarinu MC, Pica F, D'Agostini C, Salvetti M, Coccia EM, Severa M

Multiple sclerosis (Houndmills, Basingstoke, England)1 Feb 2017Cited by 27 (Europe PMC)

PMID28273784 (opens in a new tab)DOI10.1177/1352458517695892 (opens in a new tab)PepBankPUB-28273784
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueMechanism

    In TLR7-stimulated PBMC cultures from RRMS patients, Tα1 pre-treatment reduced IL-6 secretion.

    In plain wordsIn lab cultures of immune cells from multiple sclerosis donors, thymosin alpha‑1 lowered the inflammatory signal IL-6.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-6 secretion
    Study

    humann: not reported in source

    TLR7-stimulated PBMC cultures from RRMS patients
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β
    1 context sentence
    Summary · context
    we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets
  2. 02LabEx vivo tissueMechanism

    In TLR7-stimulated PBMC cultures from RRMS patients, Tα1 pre-treatment reduced IL-8 secretion.

    In plain wordsIn lab cultures of immune cells from multiple sclerosis donors, thymosin alpha‑1 lowered the inflammatory signal IL-8.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-8 secretion
    Study

    humann: not reported in source

    TLR7-stimulated PBMC cultures from RRMS patients
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β
    1 context sentence
    Summary · context
    we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets
  3. 03LabEx vivo tissueMechanism

    In TLR7-stimulated PBMC cultures from RRMS patients, Tα1 pre-treatment reduced IL-1β secretion.

    In plain wordsIn lab cultures of immune cells from multiple sclerosis donors, thymosin alpha‑1 lowered the inflammatory signal IL-1β.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseIL-1β secretion
    Study

    humann: not reported in source

    TLR7-stimulated PBMC cultures from RRMS patients
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β
    1 context sentence
    Summary · context
    we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets
  4. 04LabEx vivo tissueMechanism

    In TLR7-stimulated PBMC cultures from RRMS patients, Tα1 pre-treatment significantly increased regulatory IL-10.

    In plain wordsIn lab cultures of immune cells from multiple sclerosis donors, thymosin alpha‑1 raised the calming signal IL-10.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-10 secretion
    Study

    humann: not reported in source

    TLR7-stimulated PBMC cultures from RRMS patients
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β while significantly increasing the regulatory IL-10 and IL-35
    1 context sentence
    Summary · context
    we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets
  5. 05LabEx vivo tissueMechanism

    In TLR7-stimulated PBMC cultures from RRMS patients, Tα1 pre-treatment significantly increased regulatory IL-35.

    In plain wordsIn lab cultures of immune cells from multiple sclerosis donors, thymosin alpha‑1 raised the calming signal IL-35.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-35 secretion
    Study

    humann: not reported in source

    TLR7-stimulated PBMC cultures from RRMS patients
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β while significantly increasing the regulatory IL-10 and IL-35
    1 context sentence
    Summary · context
    we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets
  6. 06LabEx vivo tissueMechanism

    In PBMC cultures from RRMS patients, Tα1 enhanced expansion of CD19+CD24+CD38hi transitional-immature regulatory B cells.

    In plain wordsIn lab cultures of immune cells from multiple sclerosis donors, thymosin alpha‑1 increased a type of regulatory B cell.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTransitional-immature regulatory B cell subset expansion
    Study

    humann: not reported in source

    TLR7-stimulated PBMC cultures from RRMS patients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 treatment enhanced expansion of CD19+CD24+CD38hi transitional-immature and CD24low/negCD38hi plasmablast-like regulatory B cell subsets
    1 context sentence
    Summary · context
    we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets
  7. 07LabEx vivo tissueMechanism

    In PBMC cultures from RRMS patients, Tα1 enhanced expansion of CD24low/negCD38hi plasmablast-like regulatory B cells.

    In plain wordsIn lab cultures of immune cells from multiple sclerosis donors, thymosin alpha‑1 increased another type of regulatory B cell.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePlasmablast-like regulatory B cell subset expansion
    Study

    humann: not reported in source

    TLR7-stimulated PBMC cultures from RRMS patients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 treatment enhanced expansion of CD19+CD24+CD38hi transitional-immature and CD24low/negCD38hi plasmablast-like regulatory B cell subsets
    1 context sentence
    Summary · context
    we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 08HumanEndogenous levelObservational studyOther

    In patients with relapsing-remitting multiple sclerosis, the body's own serum Tα1 level was low.

    In plain wordsIn people with relapsing-remitting multiple sclerosis, the body's own thymosin alpha‑1 level in blood was low.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum Tα1 level in RRMS patients
    Study

    n: not reported in source

    serum samples from patients with RRMS
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    having found a low serum level of Thymosin-α1 (Tα1) in patients, we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets, known to dampen autoimmune inflammation.
    1 context sentence
    Summary · context
    Serum Tα1 level was measured by enzyme immunoassay.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.